REG - Proteome Sciences - Result of AGM

Proteome SciencesAnnouncement

30/04/2019 15:45

RNS Number : 6195X
Proteome Sciences PLC
30 April 2019
 


30 April 2019
 
 
 
 
 
Proteome Sciences plc
("Proteome Sciences" or the "Company")
 
Result of Annual General Meeting (AGM)
 
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 2.30 p.m. today, all resolutions were duly passed.
 
A copy of the presentation given by the CEO, Jeremy Haigh, at the AGM will be available on the Company's website tomorrow.
 
 
For further information:
 



Proteome Sciences plc




Dr Jeremy Haigh, Chief Executive Officer


Tel: +44 (0)20 7043 2116




Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer








 
Allenby Capital Limited (AIM Nominated Adviser & Broker) 




John Depasquale / Jeremy Porter


Tel: +44 (0) 20 3328 5656



About Proteome Sciences plc. (www.proteomics.com)
 
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
 
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGIMMITMBIJBML